Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

US Food and Drug Administration | Image Credit: US Food and Drug Administration

The US Food and Drug Administration (FDA)

 has accepted a supplemental New Drug Application (sNDA) for the FUROSCIX ReadyFlow Autoinjector (SCP-111), which delivers a subcutaneous injection of furosemide in <10 seconds to treat edema in patients with 

Announced on December 1, 2025, by parent company MannKind Corporation, this acceptance was supported in part by positive study results announced in August 2024, which compared a furosemide treatment via SCP-111 to the FDA-approved FUROSCIX On-body Infusor. If approved, SCP-111 could reduce administration time from 5 hours to under 10 seconds.

“By delivering treatment in under 10 seconds, the ReadyFlow Autoinjector has the potential to transform how adults with chronic heart failure or chronic kidney disease manage episodes of fluid buildup—providing faster relief, reducing hospital admissions, and lowering overall healthcare costs,” Michael Castagna, PharmD, chief executive officer at MannKind Corporation, said in a statement. “We are excited about the opportunity to bring this innovation forward and empower patients with greater convenience and control in their treatment journey.”

The study in question was an open-label, single-center, single-dose, randomized, 2-way crossover study conducted by scPharmaceuticals. Patients were included if they were between the ages of 45 and 80. Patients were excluded if they exhibited systolic blood pressure <90 mmHg at screening or baseline, a heart rate >110 BPM, serum potassium <3 or >5.5 mEq/L at screening, or other significant cardiac abnormalities, among other factors.

A total of 21 patients were included in the trial, who were then randomly assigned in a 1:1 ratio to either IV furosemide followed by SCP-111 via the autoinjector or vice versa. Each patient completed the screening, baseline, treatment, and follow-up phases of the trial. Full data from the trial will be presented at a forthcoming medical meeting or publication but has not been released yet.

Ultimately, SCP-111 showed a bioavailability of 107.3% (90% CI, 103.9-110.8), achieving the 90% confidence interval limit of 80-125%. Additionally, participants who received SCP-111 had similar urine output, urinary sodium excretion, and urinary potassium excretion at 6, 8, and 12 hours compared to IV furosemide. Patients reported a median pain score of 0 across all time points assessed, and the most common adverse events with SCP-111 were localized to the injection site and were consistent with those reported in the prescribing information for intravenous and oral furosemide.

“If approved, we believe administration of furosemide via an autoinjector would provide treatment flexibility to cardiologists and heart failure specialists and their patients,” John Tucker, chief executive officer of scPharmaceuticals, said in a statement.

SCP-111 has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2026.

MannKind Therapeutics. MannKind Announces US FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease. GlobeNewswire. December 1, 2025. Accessed December 1, 2025. 

https://www.globenewswire.com/news-release/2025/12/01/3196982/29517/en/MannKind-Announces-U-S-FDA-Accepts-for-Review-its-Supplemental-New-Drug-Application-sNDA-of-FUROSCIX-ReadyFlow-Autoinjector-for-the-Treatment-of-Edema-in-Adults-with-Chronic-Heart-.html

scPharmaceuticals, Inc. Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers. ClinicalTrials.gov identifier: NCT06167707. Updated June 27, 2024. Accessed December 1, 2025. 

https://clinicaltrials.gov/study/NCT06167707

scPharmaceuticals, Inc. scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1mL) Autoinjector. GlobeNewswire. August 12, 2024. Accessed December 1, 2025. 

https://www.globenewswire.com/news-release/2024/08/12/2928204/0/en/scPharmaceuticals-Announces-Positive-Topline-Study-Results-for-SCP-111-Furosemide-80-mg-1-mL-Autoinjector.html

Articles

The FDA has accepted a supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, which delivers furosemide subcutaneously in under 10 seconds for treating edema in chronic heart failure or kidney disease patients. This innovation could significantly reduce administration time compared to the existing FUROSCIX On-body Infusor. A study demonstrated SCP-111's bioavailability and comparable efficacy to IV furosemide, with minimal adverse events. The autoinjector offers potential treatment flexibility and convenience, with a Prescription Drug User Fee Act target action date set for July 26, 2026.

The acceptance comes on the heels of positive topline results comparing the new device to the current on-body infusor.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Chronic Kidney Disease

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

FDA News

FDA Accepts sNDA for Furosemide Autoinjector for Chronic Heart Failure and CKD

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

Factor D Inhibition Lacks Efficacy For IgAN in Phase 2 ALXN2050 Trial, With Sayna Norouzi 

New data from the phase 2 study of ALXN2050 (vemircopan) showed a non-statistically significant urine protein reduction compared to placebo, suggesting factor D inhibition is not an effective therapy for 

Findings from the randomized, placebo-controlled phase 2 trial of ALXN2050, presented by study investigator Sayna Norouzi, MD, an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center, at the 

American Society of Nephrology Kidney Week 2025

, showed a clear lack of efficacy and signaled emerging safety concerns in adults with IgAN.¹

With an evolving understanding of the pathogenesis of IgAN, clinical research has investigated the potential of immune and complement-targeted therapies to change the disease course. In line with this, ALXN2050 is an oral small-molecule designed for the selective inhibition of factor D, a serine protease largely produced in adipocytes, and the rate-limiting enzyme in the activation sequence of the alternative pathway.

“Since iptacopan showed significant benefits and aligns with our understanding of IgAN pathophysiology, it made sense to evaluate a factor D inhibitor in IgAN to see whether it could interrupt the disease process at Hit 4,” Norouzi said in an interview with 

. “But early data from this study suggest we should not continue pursuing a factor D inhibitor in IgAN.”

In the 26-week initial evaluation period, participants who were diagnosed with IgAN, had urine protein ≥1 g/d, an estimated glomerular filtration rate (eGFR) of >30 mL/min/1.73m2, and were on stable renin-angiotensin system inhibitors were randomly assigned in a 3:1:3 ratio to ALXN2050 180mg, ALXN2050 120mg, or placebo. Investigators measured the primary endpoint as the percent change in urine protein from baseline to week 26, through 24-hour urine collection.

Of the 61 enrolled patients, 47 (77.0%) completed the initial evaluation period. At baseline, mean urine protein was similar between the ALXN2050 and placebo groups (2.2 vs 2.1 g/d), as was mean eGFR (65.9 vs 70.6 mL/min/1.73m²).

By week 26, patients receiving ALXN2050 180 mg had a 26.2% reduction in urine protein compared with a 10.3% reduction with placebo, corresponding to a relative treatment effect of −17.7% (90% CI, −37.5% to 8.3%), with similar findings in sensitivity analyses. When all ALXN2050 doses were combined, the relative treatment effect was −18.6% (90% CI, −37.0% to 5.1%).

Investigators paused the phase 2 study after a serious adverse event in the lupus nephritis cohort, with a patient exhibiting jaundice and marked liver enzyme elevation consistent with acute hepatic failure, resulting in a fatal outcome. Ultimately, the trial was terminated with concerns regarding confounded data when it came to re-initiating dosing.

In the IgAN cohort, most adverse events during the initial evaluation period were mild and unrelated to treatment, and no serious treatment-related adverse events or discontinuations occurred. However, during the extension period, a patient receiving ALXN2050 180 mg experienced liver enzyme elevation with a positive rechallenge signal.

“It’s also important to talk about trials like this. We often hear about positive results and successful recruitment, but many trials encounter safety issues or disappointing efficacy,” said Norouzi. “These trials still matter; they help us learn, refine study design, and understand which therapeutic pathways are worth pursuing. This is how we continue navigating treatment development in IgA nephropathy.”

Editors’ note: Norouzi has relevant disclosures with Calliditas, Novartis, Otsuka, and Boehringer Ingelheim.

Roccatello D, Sayna Norouzi, Mohsen El Kossi, et al. Efficacy and Safety of ALXN2050 in IgAN: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. 

Journal of the American Society of Nephrology

‌Caravaca-Fontán F, Gutiérrez E, Sevillano ÁM, Praga M. Targeting complement in IgA nephropathy. 

Videos

The phase 2 study of ALXN2050 in IgAN did not meet its proteinuria endpoint, with emerging safety concerns and early termination.


Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Rachel Rosovsky, MD, is a hematologist and clinical investigator at the Massachusetts General Hospital and associate professor at Harvard Medical School.

CAVT With Anticoagulation Substantially Reduces RV/LV Diameter Ratio in PE, With Rachel Rosovsky, MD

Results from the STORM-PE trial have highlighted the superior efficacy of computer-assisted vacuum thrombectomy (CAVT) with anticoagulation (AC) in reducing right-to-left-ventricular (RV/LV) diameter ratio within 48 hours compared to AC alone in patients with intermediate to high risk of 

The elevated RV/LV diameter ratio characteristic of PE can often result in early clinical decompensation and mortality. The disease affects 1 in 1000 adults worldwide annually, reflecting a substantial reduction to quality of life. AC alone has long been considered the core of PE treatment, but growing evidence endorses endovascular therapy coupled with AC as a safe and effective method of reducing the RV/LV ratio. STORM-PE is the first randomized clinical trial to test the efficacy and safety of a mechanical thrombectomy against AC.

 sat down with Rachel Rosovsky, MD, a hematologist and clinical investigator at the Massachusetts General Hospital and associate professor at Harvard Medical School, to discuss the function of CAVT and how it stands to revolutionize PE treatment.

“The CAVT is mechanical tech from Penumbra, used to remove blood clots from arteries and veins,” Rosovsky told 

. “What makes it unique is that it’s a minimally invasive procedure, and it uses a computer-powered algorithm to enable it to quickly detect what is clot and what’s not and then remove the clot and minimize blood loss. And in our study, we found that it was a safe and fast procedure.”

STORM-PE was a prospective, randomized, placebo-controlled trial conducted over 22 locations globally. For inclusion, patients were required to have clinical signs and symptoms of acute PE with a duration of ≤14 days, objectively confirmed acute PE based on computed tomographic pulmonary angiography (CTPA), and a classification of intermediate high-risk PE as demonstrated by right ventricular dysfunction RV/LV ratio ≥1 on CTPA, among other requirements. Exclusion criteria included hemodynamic instability with cardiac arrest, obstructive shock, or persistent hypotension and allergy-, hypersensitivity-, or heparin-induced thrombocytopenia.

A total of 100 patients were included in the trial and were randomly assigned in a 1:1 ratio to either CAVT (n = 47) or AC (n = 53). The mean age was 59.5 +/- 13.22 years in the CAVT arm and 61.2 +/- 14.19 years in the AC arm. The mean time from symptom onset to PE hospital admission was 3 days (interquartile range [IQR] 0-6) in the CAVT arm and 2 days (0-6) in the AC arm (

 = 0.889). All patients had elevated cardiac biomarkers, and 59.1% in the CAVT arm and 74.5% in the AC arm had both elevated troponin and BNP or NT-proBNP.

After 48 hours, the CAVT arm saw a significantly greater change in RV/LV ratio (0.52 +/- 0.37 vs 0.24 +/- 0.4), with a difference of 0.27 (95% CI, 0.12-0.43; 

 <.001). CAVT treatment also resulted in earlier normalization of vital signs, and there was little difference in major adverse events across both arms (CAVT 4.3% vs AC 7.5%; 

“I think that this is a game changer,” Rosovsky said. “This is a groundbreaking trial. It really allows patients to think about an alternative or additional therapy that can really help them feel better and improve faster.”

Editor’s Note: Rosovsky reports disclosures with BMS, Janssen, Dava, and Inari Medical.

Lookstein RA, Konstantinides SV, Weinberg I, et al. Randomized controlled trial of mechanical thrombectomy with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism: Primary outcomes from the storm-PE trial. Circulation. Published online November 3, 2025. 

Penumbra Inc. Comparison of Two Pulmonary Embolism Treatments. ClinicalTrials.gov Identifier: NCT05684796. Updated November 17, 2025. Accessed November 25, 2025. 

https://clinicaltrials.gov/study/NCT05684796

Rosovsky discusses the revolutionary new therapy’s potential to revolutionize the field of pulmonary embolism treatment.

Venous Thromboembolism

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

In new follow-up data from a large community cohort, findings suggest 

 may have a far more favorable long-term course than hospital-based studies have often suggested.

Rune Kjærsgaard Andersen, MD, PhD, and a team of other investigators had set out to explore whether progression and remission rates of HS are the same in community settings and hospital settings. The investigators also wrote this prospective cohort study to identify any baseline factors linked with HS remission and progression to severe disease.

Andersen et al pointed to most HS prevalence and severity estimates originating from tertiary care; therefore accurate representation of the broader HS population was seen as essential. Prior data suggest 22% of those with HS develop severe disease within only 2 years, though this statistic’s reflection on the entire HS community had been unclear prior to the current analysis.

“To compare discrepancies between hospital and community cohorts, we performed a 10-year follow-up study of a municipality-based HS cohort focusing on HS progression and remission rates,” Andersen and coauthors wrote.

In this study, Andersen and coauthors presented a follow-up assessment of HS severity within an unselected, municipality-based cohort originally drawn from GESUS in the period between January 2010 - October 2013. GESUS invited every individual within Denmark's Næstved municipality in Denmark who was at least 20 years old. There were 21,205 who participated as participated.

During each participant's initial visit, the investigative team asked them to full out a paper questionnaire inquiring about well-being, health status, depressive symptoms, and dermatologic screening information. Each of the subjects also underwent a physical evaluation. In early 2023, those who had screened positive for HS during the baseline period were informed and asked to complete a follow-up survey.

Andersen and colleagues' aim in conducting this follow-up was to determine rates of HS progression and remission, as well as to evaluate any baseline demographic qualities found to be associated with changes in HS activity. They categorized HS severity at both time points as mild, moderate, or severe via a modified Hurley staging system. Additionally, Andersen et al determined the proportion of subjects whose HS progressed to severe, as well as the proportion attaining remission.

Cox proportional hazards models were also implemented by the investigative team with the aim of evaluating any baseline demographic factors showed a link with shifts in severity by 2023. The team's data analysis took place from March 2024 - September 2025.

There were 107 individuals with HS who the investigators included in the analysis.

 These subjects were 82.2% female and 17.8% male, with a mean (SD) age of 47.1 (8.8) years. During the time of enrollment, 53.3% were found by the team to have mild disease, 18.7% with moderate disease, and 28.0% with severe disease. Over the follow-up interval, 16.9% of patients showing non-severe HS reported disease progression. They also found 13.0% advanced to severe disease.

Overall, Andersen and coauthors' findings suggested 71.0% of all individuals showed some degree of HS regression and 63.6% attained a complete level of HS remission.

 When broken down by original severity, the investigators found full remission had been achieved by 73.7% of participants with mild HS, 60.0% of participants with moderate disease, and 46.7% of those with severe disease. In their Cox regression analysis, the investigative team did not identify any baseline demographic predictors of shifts in severity at follow-up.

The findings suggest that hospital-based estimates may have exaggerated the likelihood of HS worsening and underestimated the frequency of the skin disease's remission.

 In this community sample, the team found risk of progression to severe HS was 10.4 times lower, and remission took place 3.8 times more often, compared with rates typically observed in hospital settings.

“Limitations were HS case definition and severity staging that relies on self-reported information; remission defined as a symptom-free period of 6 months; a single follow-up time (which may not account for the fluctuating nature of HS); and a relatively low participation rate,” the team concluded.

Kjærsgaard Andersen R, Pedersen OBV, et al. Hidradenitis Suppurativa Remission and Progression in a Community Setting. JAMA Dermatol. Published online November 26, 2025. 

Kokolakis G﻿, Wolk K﻿, Schneider-Burrus S﻿, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236(5):421-430. 

A recent study indicates that hidradenitis suppurativa (HS) may have a more favorable long-term prognosis in community settings compared to hospital-based data. Conducted by Rune Kjærsgaard Andersen, MD, PhD, and colleagues, the study followed a cohort from Denmark's Næstved municipality over ten years. Results showed that 71% of participants experienced some HS regression, with 63.6% achieving complete remission. The study found no baseline demographic predictors for changes in HS severity. These findings suggest hospital-based estimates may overstate HS progression and understate remission rates.

These new data indicate a potential lack of accuracy in hospital-based data on hidradenitis suppurativa (HS) outcomes among those in nonclinical settings.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Long-Term Course of HS Disease More Favorable Than Previous Estimates

Shagun Bindlish, MD, FACP, FOMA, DABOM, DACLM, is an internist and diabetologist with advanced expertise in obesity and lifestyle medicine. She serves as medical and scientific chair for the ADA Northern California and is the founder of the Golden State Obesity Society. An educator at Touro University California and University at Sea CME, she has trained providers worldwide in metabolic health. 

Recognized with the Obesity Medicine Association’s Outstanding Contribution Award in 2024, she is also nominated by her peers for the Compassionate Physician of the Year Award by the California Medical Association. Her work focuses on advancing diabetes and obesity care through innovation, education, and advocacy.

Shagun Bindlish, MD, FACP, FOMA, DABOM, DACLM

Each November, as blue lights illuminate buildings and ribbons mark Diabetes Awareness Month, we’re reminded of the millions living with diabetes and of the millions more standing quietly at the edge of diagnosis. For clinicians, it’s time to look beyond the numbers on a glucose meter and confront a more profound truth: 

 is not just a disease of high blood sugar; it reflects a deeper metabolic imbalance.

Behind every elevated HbA1c lies a story of metabolic overload, a body struggling to manage excess energy, inflamed adipose tissue sending distress signals, and β-cells fighting to maintain equilibrium. Obesity and diabetes are not parallel epidemics; they are interwoven threads of the same metabolic fabric. This month

awareness must mean integration, uniting how we think, talk, and care for these interconnected conditions.

The Metabolic Bridge Between Obesity and Type 2 Diabetes

Obesity reshapes metabolism long before a single glucose reading turns abnormal. Adipose tissue, once thought to be inert, is a dynamic endocrine organ. As fat cells expand, they release free fatty acids and pro-inflammatory cytokines such as TNF-α and IL-6, while adiponectin, the guardian of insulin sensitivity, declines. This inflammatory cascade disrupts insulin signaling in the liver and muscle, forcing pancreatic β-cells to secrete more insulin just to maintain normalcy.

Over time, the relentless demand leads to β-cell exhaustion. The pancreas cannot keep up; glucose rises. What we call “type 2 diabetes” is often the final act of years of unseen metabolic struggle.

The lesson is clear: Obesity and Diabetes are not separate diseases but biological partners along a shared continuum.

Why Some with Obesity Develop Diabetes, and Others Don’t

Not everyone with obesity develops diabetes, and understanding why is key to prevention. Two individuals with identical BMIs may walk entirely different metabolic paths. The difference lies in where fat is stored and how it behaves.

Visceral and ectopic fat nestled in the liver, pancreas, and muscle acts as a metabolic saboteur, promoting insulin resistance. In contrast, subcutaneous fat can serve as a safer storage reservoir. Those able to expand subcutaneous depots without spilling fat into vital organs remain metabolically healthier, even at higher weights.

The second determinant is β-cell resilience. Genetics, early nutrition, ethnicity, and even prenatal exposures influence β-cell endurance. For instance, South Asian and Hispanic individuals develop diabetes at lower BMI thresholds because their β-cell reserve is smaller. Add to those modern stressors, poor sleep, inactivity, processed diets, and the balance tips faster.

Identifying risk early allows us to intervene before β-cells exhaustion.

 BMI and waist circumference remain simple yet powerful markers of visceral adiposity.

 Fasting glucose, HbA1c, fasting insulin, and, when needed, an oral glucose tolerance test reveal early dysglycemia.

 Family history, gestational diabetes, PCOS, sleep apnea, ethnicity, and medication history refine assessment.

 Regular HbA1c, waist measurement, and even continuous glucose monitoring in high-risk individuals can expose subtle metabolic shifts.

A 5 – 10% weight loss can reduce diabetes risk by half. Mediterranean-style nutrition, daily movement combining aerobic and strength training, and adequate sleep can also reduce diabetes risk. Yet sustaining it requires behavioral scaffolding: goal setting, self-monitoring, and community support.

2. Pharmacotherapy: The Metabolic Revolution

A new generation of therapies is redefining possibilities. GLP-1 receptor agonists, such as semaglutide and dual GIP/GLP-1 agents like tirzepatide deliver unprecedented improvements in both weight and glycemia. When viewed not as shortcuts but as metabolic restoratives, these medications empower patients and clinicians alike. For many, they are the bridge from chronic struggle to sustainable success.

3. Metabolic Surgery: Durable Transformation

For patients with severe obesity (BMI ≥ 40 kg/m² or ≥ 35 kg/m² with comorbidities), bariatric or metabolic surgery offers a durable impact, often achieving diabetes remission through hormonal and metabolic reset. The key lies in lifelong follow-up: nutritional, psychological, and medical.

Together, these pillars form a continuum of lifestyle first, pharmacotherapy next, and surgery when indicated.

Integrating Care: Healing the Whole Metabolism

Too often, diabetes clinics focus on glucose while obesity programs focus on weight. This division misses the point. Both conditions spring from the same root cause: disordered energy balance and impaired insulin action. An integrated metabolic care uniting endocrinology, obesity medicine, nutrition, psychology, and exercise physiology delivers the best outcomes.

Technology now enhances this integration: continuous glucose monitors, smart scales, and AI-based coaching can personalize interventions in real time. But integration is not just logistical, it’s philosophical. By treating obesity and diabetes together, we move from symptom control to root-cause medicine.

 promise greater synergy across glucose and weight regulation.

 will soon allow personalized interventions based on insulin resistance or β-cell profile.

 are transforming lifestyle monitoring and early prevention.

 recognizes that metabolic disease begins decades before diagnosis.

Obesity Medicine Association (OMA) Clinical Practice Guidelines

: Comprehensive frameworks for evidence-based care.

: An interactive roadmap integrating pharmacotherapy, behavior, and surgery.

: Education on communication, bias reduction, and metabolic comorbidities.

This Diabetes Awareness Month, let’s redefine awareness itself. It’s no longer enough to chase glucose targets. We must confront the metabolic roots that feed the epidemic. Every conversation about diabetes must include obesity; every discussion about weight must include metabolic health.

Diabetes Awareness Month highlights the interconnectedness of obesity and type 2 diabetes, emphasizing the need for integrated care. Obesity and diabetes are not separate diseases but part of a shared metabolic continuum. The distribution and behavior of fat, along with β-cell resilience, determine diabetes risk. Early risk assessment and intervention are crucial. Management involves lifestyle changes, pharmacotherapy, and metabolic surgery. Integrated care, combining endocrinology, obesity medicine, and technology, addresses the root causes of metabolic disorders, moving beyond symptom control to holistic treatment.

Shagun Bindlish, MD, emphasizes the urgent need to integrate diabetes and obesity care, addressing their shared metabolic roots for better health outcomes.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Beyond Blood Sugar: Reframing Diabetes Awareness Through the Lens of Obesity

Michelle O'Donoghue, MD, is the McGillycuddy-Logue Endowed Chair in Cardiology at Brigham and Women's Hospital and associate professor at Harvard Medical School

O’Donoghue discusses the results of this analysis of the FOURIER trial, highlighting that no limit was found for lowered LDL-C improving MACE risk.

Atherosclerotic Cardiovascular Disease

Dyslipidemia

Very Low LDL-C Improves Risk of MACE in Patients With ASCVD, With Michelle O’Donoghue, MD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

State- and local-level disparities in the availability of gastroenterologist care disproportionately affect patients with IBD and populations living in rural and high-poverty areas.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

However, a related editorial from University of Rome was quick to point out possibly sizable placebo effects in the trial.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Meta-analysis shows semaglutide lowers cardiovascular and kidney risks while supporting safety in adults with chronic kidney disease.


Semaglutide Provides Cardiorenal Benefits in CKD With or Without Diabetes

This global analysis highlights the incidence of psoriasis around the world by 2025, noting various distinctions in region, age groups, and sex.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

Vinay Mehta, MD: Board-certified allergist/immunologist with Allergy & Asthma Associates of Southern California

Board-certified allergist shares how clinicians can better recognize and prevent atopic dermatitis in patients with skin of color, addressing pigmentation.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

Brandon Yan, MD, is a resident physician at the University of California.

Yan discusses the reversion of 50-year trends in mortality and the steps needed to reduce these rates back to pre-pandemic levels.

Cardiomyopathy

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Addressing Post-Pandemic Cardiovascular Mortality Rate Increases, With Brandon Yan, MD

This research, presented at the SDPA Fall Conference, highlights a consensus report proposing the first formal set of dermoscopy proficiency expectations for PAs.

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs 

Marcus Shaker, MD, a professor of pediatrics and medicine at the Dartmouth Geisel School of Medicine

Screenshot 2025-11-06 at 10.12.42 AM.png

A quick guide for clinicians on epinephrine dosing, optimal observation periods, and the role of tryptase and other labs in anaphylaxis care.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Latest News

FDA Accepts sNDA for Furosemide Autoinjector for Chronic Heart Failure and CKD

Factor D Inhibition Lacks Efficacy For IgAN in Phase 2 ALXN2050 Trial, With Sayna Norouzi

CAVT With Anticoagulation Substantially Reduces RV/LV Diameter Ratio in PE, With Rachel Rosovsky, MD

Long-Term Course of HS Disease More Favorable Than Previous Estimates

Beyond Blood Sugar: Reframing Diabetes Awareness Through the Lens of Obesity